Aptamer-drug conjugation for targeted tumor cell therapy.

Michael J Donovan, Ling Meng, Tao Chen, Yunfei Zhang, Kwame Sefah, Weihong Tan

Journal: Methods in molecular biology (Clifton, N.J.) 2011;764():141-52

PMID: 21748638

Abstract

Aptamers developed for applications in cancer therapy can improve the efficacy of drug treatment and enhance molecular imaging. Aptamers for these purposes are generated from SELEX (Systematic Evolution of Ligands by EXponential enrichment), more precisely cell-based SELEX, a process described in detail in this chapter. Experimental applications are also provided for aptamer-based drugs.

Address: Department of Chemistry, Shands Cancer Center, Moffitt Cancer Center, Center for Research at Bio/Nano Interface, UF Genetics Institute and McKnight Brain Institute, University of Florida, Gainesville, FL, USA. [email protected]

DOI: 10.1007/978-1-61779-188-8_9

Link outs

Free resources

Medical:

https://medlineplus.gov/leukemia.html

Other Literature Sources:

https://www.lens.org/lens/search/patent/list?q=ref...

Subscription / membership required

Full Text Sources:

https://doi.org/10.1007/978-1-61779-188-8_9

MeSH Terms: Antineoplastic Agents, Aptamers, Nucleotide, Biotin, Cell Line, Tumor, Doxorubicin, Humans, Leukemia, Ligands, Molecular Targeted Therapy, SELEX Aptamer Technique, Streptavidin